Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489468 | 1.00 | CREBBP (0.33) | CREBBPRIPK1ROCK2TBK1GRM2 | |
| SCHEMBL31489543 | 0.97 | RIPK1 (0.33) | CREBBPRIPK1ROCK2TBK1KIT | |
| SCHEMBL31489789 | 0.97 | RIPK1 (0.33) | CREBBPRIPK1ROCK2TBK1KIT | |
| SCHEMBL31489724 | 0.87 | RIPK1 (0.35) | CREBBPRIPK1ROCK2TBK1KIT | |
| SCHEMBL31489821 | 0.87 | RIPK1 (0.35) | CREBBPRIPK1ROCK2TBK1KIT | |
| SCHEMBL31489497 | 0.86 | CREBBP (0.35) | CREBBPRIPK1ROCK2TBK1BRD4 | |
| SCHEMBL31489515 | 0.86 | RIPK1 (0.35) | CREBBPRIPK1ROCK2 | |
| SCHEMBL31489201 | 0.86 | RIPK1 (0.35) | CREBBPRIPK1ROCK2 | |
| SCHEMBL31489584 | 0.85 | MKNK1 (0.34) | CREBBPRIPK1ROCK2KIT | |
| SCHEMBL31489856 | 0.85 | MKNK1 (0.34) | CREBBPRIPK1ROCK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |